Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 1/20 | 0.79 |
| ▸ | CTSK | P43235 | 12/20 | 0.59 |
| ▸ | CTSS | P25774 | 4/20 | 0.58 |
| ▸ | CTSL | P07711 | 4/20 | 0.58 |
| ▸ | CTSB | P07858 | 1/20 | 0.58 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.56 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.56 |
| ▸ | PSMB2 | P49721 | 1/20 | 0.56 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.52 |
| ▸ | CAPN2 | P17655 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2723328 | 1.00 | SYK (0.79) | SYKCTSKCTSSCTSLCTSB | |
| SCHEMBL2723705 | 1.00 | SYK (0.79) | SYKCTSKCTSSCTSLCTSB | |
| SCHEMBL3271846 | 0.88 | SYK (0.82) | SYKCTSKCTSSCTSLCTSB | |
| SCHEMBL2627398 | 0.88 | SYK (1.00) | SYKCTSKCTSSCTSLCTSB | |
| SCHEMBL3582905 | 0.88 | SYK (0.82) | SYKCTSKCTSSCTSLCTSB | |
| SCHEMBL6310853 | 0.88 | SYK (0.82) | SYKCTSKCTSSCTSLCTSB | |
| SCHEMBL6310843 | 0.88 | SYK (0.82) | SYKCTSKCTSSCTSLCTSB | |
| SCHEMBL2627375 | 0.88 | SYK (0.82) | SYKCTSKCTSSCTSLCTSB | |
| SCHEMBL6310847 | 0.88 | SYK (0.82) | SYKCTSKCTSSCTSLCTSB | |
| SCHEMBL3271109 | 0.87 | SYK (0.80) | SYKCTSKCTSSCTSLCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 93 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12285431-B2 | Treatment of Rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors | PHARMACOSMOS HOLDING A/S (DK) | 2025-04-29 | — | — | US | disclosed |
| US-20240109906-A1 | CDK INHIBITORS | G1 THERAPEUTICS, INC. (US) | 2024-04-04 | — | — | US | disclosed |
| US-20230381189-A1 | TRANSIENT PROTECTION OF NORMAL CELLS DURING CHEMOTHERAPY | G1 THERAPEUTICS, INC. (US) | 2023-11-30 | — | — | US | disclosed |
| US-20230364098-A1 | HSPC-SPARING TREATMENTS FOR RB-POSITIVE ABNORMAL CELLULAR PROLIFERATION | G1 THERAPEUTICS, INC. (US) | 2023-11-16 | — | — | US | disclosed |
| US-11717523-B2 | Transient protection of normal cells during chemotherapy | G1 THERAPEUTICS, INC. (US) | 2023-08-08 | — | — | US | disclosed |
| US-20230241059-A1 | ANTI-NEOPLASTIC COMBINATIONS AND DOSING REGIMENS USING CDK4/6 INHIBITOR COMPOUNDS TO TREAT RB-POSITIVE TUMORS | G1 THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | US | disclosed |
| US-11654148-B2 | HSPC-sparing treatments for RB-positive abnormal cellular proliferation | G1 THERAPEUTICS, INC. (US) | 2023-05-23 | — | — | US | disclosed |
| US-11446295-B2 | Anti-neoplastic combinations and dosing regimens using CDK4/6 inhibitor compounds to treat Rb-positive tumors | G1 THERAPEUTICS, INC. (US) | 2022-09-20 | — | — | US | disclosed |
| US-20220175780-A1 | TREATMENT OF RB-NEGATIVE TUMORS USING TOPOISOMERASE INHIBITORS IN COMBINATION WITH CYCLIN DEPENDENT KINASE 4/6 INHIBITORS | PHARMACOSMOS A/S (DK) | 2022-06-09 | — | — | US | disclosed |
| CN-108283644-B | Transient protection of normal cells during chemotherapy | G1治疗公司 | 2022-03-18 | — | — | CN | disclosed |
| US-20140142299-A1 | CDK Inhibitors | G1 THERAPEUTICS, INC. (US) | 2014-05-22 | — | — | US | disclosed |
| US-20140142306-A1 | CDK Inhibitors | G1 THERAPEUTICS, INC. (US) | 2014-05-22 | — | — | US | disclosed |
| US-8691830-B2 | CDK inhibitors | G1 THERAPEUTICS, INC. (US) | 2014-04-08 | — | — | US | disclosed |
| US-8598197-B2 | CDK inhibitors | G1 THERAPEUTICS, INC. (US) | 2013-12-03 | — | — | US | disclosed |
| US-8598186-B2 | CDK inhibitors | G1 THERAPEUTICS, INC. (US) | 2013-12-03 | — | — | US | disclosed |
| US-20130237544-A1 | CDK INHIBITORS | G1 THERAPEUTICS, INC. (US) | 2013-09-12 | — | — | US | disclosed |
| US-20130237534-A1 | CDK INHIBITORS | G1 THERAPEUTICS, INC. (US) | 2013-09-12 | — | — | US | disclosed |
| US-20130237533-A1 | CDK Inhibitors | G1 THERAPEUTICS, INC. (US) | 2013-09-12 | — | — | US | disclosed |
| EP-2632467-A1 | CDK INHIBITORS | G1 Therapeutics, Inc. (US) | 2013-09-04 | — | — | EP | disclosed |
| WO-2012061156-A1 | CDK INHIBITORS | TAVARES FRANCIS X (US) | 2012-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130237534-A1 | CDK INHIBITORS | CDK3, CDK9, CDK6 | SYK 1923/4885CTSK 1426/4885CTSS 2527/4885 |
| US-20240109906-A1 | CDK INHIBITORS | CDK3, CDK9, CDK6 | SYK 1923/4885CTSK 1426/4885CTSS 2527/4885 |
| US-20230364098-A1 | HSPC-SPARING TREATMENTS FOR RB-POSITIVE ABNORMAL CELLULAR PROLIFERATION | RB1, CDK4, CDKN1A | SYK 2396/4885CTSK 2543/4885CTSS 2763/4885 |
| US-12285431-B2 | Treatment of Rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors | RB1, CDK4, CDK6 | SYK 2925/4885CTSK 2201/4885CTSS 3037/4885 |
| US-11446295-B2 | Anti-neoplastic combinations and dosing regimens using CDK4/6 inhibitor compounds to treat Rb-positive tumors | CDK4, RB1, BTK | SYK 67/4885CTSK 2526/4885CTSS 3380/4885 |
| US-20220175780-A1 | TREATMENT OF RB-NEGATIVE TUMORS USING TOPOISOMERASE INHIBITORS IN COMBINATION WITH CYCLIN DEPENDENT KINASE 4/6 INHIBITORS | RB1, CDK4, CDK6 | SYK 2925/4885CTSK 2201/4885CTSS 3037/4885 |
| US-20230381189-A1 | TRANSIENT PROTECTION OF NORMAL CELLS DURING CHEMOTHERAPY | CDK6, CCNC, MCL1 | SYK 4431/4885CTSK 1517/4885CTSS 2739/4885 |
| US-20140142306-A1 | CDK Inhibitors | CDK3, CDK9, CDK6 | SYK 1923/4885CTSK 1426/4885CTSS 2527/4885 |
| US-20130237533-A1 | CDK Inhibitors | CDK3, CDK9, CDK6 | SYK 1923/4885CTSK 1426/4885CTSS 2527/4885 |
| US-20230241059-A1 | ANTI-NEOPLASTIC COMBINATIONS AND DOSING REGIMENS USING CDK4/6 INHIBITOR COMPOUNDS TO TREAT RB-POSITIVE TUMORS | CDK4, RB1, BTK | SYK 67/4885CTSK 2526/4885CTSS 3380/4885 |
| US-20140142299-A1 | CDK Inhibitors | CDK3, CDK9, CDK6 | SYK 1923/4885CTSK 1426/4885CTSS 2527/4885 |
| US-11654148-B2 | HSPC-sparing treatments for RB-positive abnormal cellular proliferation | RB1, CDK4, CDKN1A | SYK 2396/4885CTSK 2543/4885CTSS 2763/4885 |
| US-11717523-B2 | Transient protection of normal cells during chemotherapy | CDK6, CCNC, MCL1 | SYK 4431/4885CTSK 1517/4885CTSS 2739/4885 |
| US-20130237544-A1 | CDK INHIBITORS | CDK3, CDK9, CDK6 | SYK 1923/4885CTSK 1426/4885CTSS 2527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.